Medical Information Only. Consult your healthcare provider before enrolling in any clinical trial.
District of Columbia: below-average open trial sites
727 of 2,316 in-state trials are recruiting (31%); below the 37% national average by 6 percentage points.
According to ClinicalTrials.gov-derived indexes, District of Columbia sits in the upper half of US states by in-state trial count (#25 of 52 states by registered in-state trial count).
District of Columbia: 2,316 US clinical trials with in-state sites, 727 recruiting.
District of Columbia has 2,316 registered US clinical trials with a study site in-state, 727 of them currently recruiting (below the 37% national average by 6 percentage points). 599 of these trials are in Phase 3 (late-stage) and 560 in Phase 2. The most frequently studied condition in District of Columbia is HIV Infections, with 125 linked trials.
Mid-pack research density
District of Columbia sits in the upper half of the state corpus, so volume is meaningful but not hub-scale. Use condition and sponsor rollups below to see what drives the in-state mix.
Below-average open enrollment
District of Columbia still shows 727 recruiting of 2,316 in-state trials (31% open), but below the 37% national average by 6 percentage points, so archived statuses weigh heavier than the national baseline.
- 31%
- open (below national share)
- 727
- still recruiting despite cool share
- 560
- Phase 2 rows in this footprint
- 125
- top: HIV Infections
Recruiting share is below the 37% national average by 6 percentage points. Counts include every study with at least one recorded site in the state. Registry reference only, not medical advice.
District of Columbia vs all states by indexed in-state trial count
Where this state's ClinicalTrials.gov site count sits among every state with at least one listed trial (coverage density, not care quality)
2,316 Top 48% more indexed trials than 52% of 52 states
States, banded by indexed in-state trial count
Each bar is a band; taller bars hold more states. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov · 2026-08-08
Key findings
What ClinicalTrials.gov does not surface for District of Columbia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
District of Columbia open-enrollment share sits below the national baseline.
727 of 2,316 in-state trials (31.4%) are recruiting, against 37% nationally (-5.6 percentage points). Counts include every study with at least one recorded site in the state.
-
Washington D.C. dominates District of Columbia's trial geography.
Washington D.C. lists 2,307 of 2,316 in-state trials (99.6%) across 742 named facilities. Cities need five or more listed trials to appear here; locations are as filed by sponsors.
-
HIV Infections is the most-studied condition in District of Columbia.
125 of 2,316 in-state trials (5.4%) list HIV Infections. That is a local concentration figure, not a national disease ranking.
-
District of Columbia sponsorship is fragmented across many organizations.
National Cancer Institute (NCI) appears on 90 of 2,316 in-state trials (3.9%). Sponsor identity is as filed on ClinicalTrials.gov.
-
1,036 District of Columbia trials carry a completed status.
1,036 of 2,316 (44.7%) are completed. The open share above is the remainder that still lists recruiting.
By Status
| Status | Trial count |
|---|---|
| Completed | 1,036 |
| Recruiting | 727 |
| Active | 553 |
By Phase
| Phase | Trial count |
|---|---|
| Phase 3 | 599 |
| Phase 2 | 560 |
| NA | 424 |
| Phase 1 | 295 |
| Phase 4 | 81 |
| Early Phase 1 | 6 |
Top Conditions
Top Sponsors
Where trials run in District of Columbia
Washington D.C. carries 2,307 of District of Columbia's 2,316 indexed trials (100%) across 742 named sites, ahead of Georgetown at 5. 2 cities clear five listed trials, together naming 746 distinct sites.
| City | Trials | Listed sites |
|---|---|---|
| Washington D.C. | 2,307 | 742 |
| Georgetown | 5 | 4 |
Distinct trials and named sites per city, as filed with ClinicalTrials.gov; cities under five trials omitted. Vintage 2026-08-08.
Trial size large
District of Columbia's in-state trials target 4,246 patients on average (p69 by trial size among 52 states with enrollment data), larger, multi-site studies than most states.
District of Columbia: in-state trial volume sits mid-pack
Geography is concentrated: Washington D.C. alone accounts for 100% of District of Columbia's indexed trials (2,307 of 2,316), with Georgetown a distant second at 5.
Phase mix: 599 Phase 3 vs 560 Phase 2 (balanced across stages).
Top condition: HIV Infections (125 trials); top sponsor National Cancer Institute (NCI) (90).
mid-volume · mid-open figures (2,316 trials · 31% open) describe registry geography under the trial size large read, not clinic capacity or protocol fit. Confirm status on ClinicalTrials.gov before acting.
States near District of Columbia on average trial size
Cross-state peers under the trial size large read (mid-volume · mid-open), not the same-state browse list.